Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced a call for proposals for a new Accelerator Grant Program. Designed to help facilitate breakthroughs in science and medicine, this year’s Accelerator Grant Program will award up to $50,000 towards the cost of research in Quanterix’ Accelerator Lab to help advance the most exciting biomarker research using Quanterix’ ultrasensitive Simoa technology.
Our Simoa technology powers groundbreaking research that can disrupt the way diseases are diagnosed and treated, and we want to make sure that technology remains within reach for the most promising discoveries. Our rapid growth has allowed us to expand the capabilities of our in-house pharmaceutical services lab, and the Accelerator Grant Program extends the reach of these resources, giving more researchers the opportunity to leverage the science of Simoa for their projects with the goal of improving today’s healthcare system.”
Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix
This year, special consideration will be given to proposals leveraging the Simoa CorPlex 10 Plex planar array or other Simoa planar arrays, which enable the accuracy, sensitivity and reproducibility needed to address many of today’s unmet needs in oncology, immuno-oncology and other research areas. Specifically, proposals focused on tumor-shrinking markers, hot and cold tumor differentiation, cytokine release syndrome, cytokine release neurotoxicity, CAR T-cell therapies, patient stratification, predictive biomarkers, and liquid biopsies will be given special attention as they address some of the greatest unmet needs in research today.
Biomarker research continues to provide a treasure trove of information powering medical breakthroughs and we are optimistic that together we’ll be able to drive change. We feel there is a lot of untapped potential in this area that could help us take down the most lethal diseases, including cancer. That’s why we’re seeking applicants with a focus across these specific areas in which biomarkers have already shown significant promise.”
Kevin Hrusovsky
Quanterix’ state-of-the-art Accelerator Lab is a dedicated CLIA-certified laboratory environment for custom assay development and clinical sample testing. Staffed with a large team of scientists dedicated exclusively to Accelerator projects, to which grant recipients will also have access, the Lab offers some of the greatest ultra-sensitive assay development and instrument operation experiences available. Since its launch in 2014, the Lab has powered considerable advancements in disease detection and drug development, helping researchers obtain quick, robust data that would otherwise take more time and added resources.
To be considered for the grant, all interested parties must submit their proposals by June 30, 2019. Recipients will be notified by July 31, 2019.
Quanterix to release second quarter 2019 financial results and host conference call on Tuesday, August 6, 2019